Daily feed · SEC Form 4 filings
Significant insider purchases — Apr 10, 2018
Open-market purchases of at least $50,000 — or at least $500,000 when the buyer is a 10% owner.
| Trade | Reported (ET) | Company | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 9, 2018 PForm 4 → | Apr 9, 5:19 pm EDT | INTERCEPT PHARMACEUTICALS INCICPT | Francesco Micheli10% Owner | 390,625 | $64.00 | $25,000,000 | 6,845,578 | +6.05% | plan? |
| Apr 9, 2018 PForm 4 → | Apr 9, 5:20 pm EDT | INTERCEPT PHARMACEUTICALS INCICPT | Genextra S.p.A.10% Owner | 390,625 | $64.00 | $25,000,000 | 6,845,578 | +6.05% | plan? |
| Apr 9, 2018 PForm 4 → | Apr 9, 7:36 pm EDT | INTERCEPT PHARMACEUTICALS INCICPT | Daniel BradburyDirector | 7,812 | $64.00 | $499,968 | 11,642 | +204% | plan? |
| Apr 9, 2018 PForm 4 → | Apr 9, 7:36 pm EDT | INTERCEPT PHARMACEUTICALS INCICPT | Mark PruzanskiCEO & President, Director | 7,812 | $64.00 | $499,968 | 576,564 | +1.37% | plan? |
| Apr 6, 2018 PForm 4 → | Apr 9, 4:50 pm EDT | Aclaris Therapeutics, Inc.ACRS | Stephen A. TullmanDirector | 26,700 | $16.54 | $441,618 | 157,507 | +20.4% | plan? |
| Apr 6, 2018 PForm 4 → | Apr 9, 5:11 pm EDT | CARMAX INCKMX | Peter J BensenDirector | 5,000 | $62.12 | $310,600 | 5,165 | +3,030% | plan? |
| Apr 9, 2018 PForm 4 → | Apr 9, 7:37 pm EDT | INTERCEPT PHARMACEUTICALS INCICPT | Keith Michael GottesdienerDirector | 1,171 | $64.00 | $74,944 | 5,001 | +30.6% | plan? |
A trading day runs to 4:00 pm ET; filings accepted later appear on the next trading day. Rows aggregate a filing’s matching transaction lines — see the methodology for the exact roll-up rules.